Reuters logo
BRIEF-Argos says independent data monitoring committee recommends discontinuation of the adapt Phase 3 clinical trial of rocapuldencel-T
February 22, 2017 / 1:19 PM / 8 months ago

BRIEF-Argos says independent data monitoring committee recommends discontinuation of the adapt Phase 3 clinical trial of rocapuldencel-T

Feb 22 (Reuters) - Argos Therapeutics Inc

* Independent data monitoring committee recommends discontinuation of the adapt Phase 3 clinical trial of rocapuldencel-T in metastatic renal cell carcinoma for futility following its planned interim data review

* Argos - IDMC concluded that study was unlikely to demonstrate a statistically significant improvement in overall survival in combination treatment arm

* Argos Therapeutics Inc - is analyzing preliminary adapt trial data set and plans to discuss data with U.S. Food and Drug Administration

* Argos Therapeutics Inc - company plans to leave adapt trial open while company conducts its ongoing data review and discussions with FDA

* Argos Therapeutics Inc - IDMC noted that rocapuldencel-T was generally well-tolerated in trial

* Says based on analyses and discussions, will make a determination as to next steps for rocapuldencel-T clinical program Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below